Science research news Return to previous page
Article Released Wed-16th-August-2006 17:17 GMT
Contact: Ruth Institution: Nature Publishing Group
 Avian flu’s Achilles’ heel, Stopping the silent spread

The molecular structure of a key avian influenza protein reveals a quirk that could be used to design more potent drugs against pandemic flu; The use of unvaccinated 'sentinel' birds may not always prevent the silent spread of the H5N1 virus through vaccinated flocks

WWW.NATURE.COM/NATURE

This press release is copyright Nature. VOL.442 NO.7104 DATED 17 AUGUST 2006

This press release contains:

• Summaries of newsworthy papers:

Immunology: Avian flu’s Achilles’ heel

Avian flu: Stopping the silent spread


Editorial contacts: While the best contacts for stories will always be the authors themselves, in some cases the Nature editor who handled the paper will be available for comment if an author is unobtainable. Editors are contactable via Ruth Francis on +44 20 7843 4562. Feel free to get in touch with Nature's press contacts in London, Washington and Tokyo (as listed at the end of this release) with any general editorial inquiry.

Warning: This document, and the Nature papers to which it refers, may contain information that is price sensitive (as legally defined, for example, in the UK Criminal Justice Act 1993 Part V) with respect to publicly quoted companies. Anyone dealing in securities using information contained in this document or in advanced copies of Nature’s content may be guilty of insider trading under the US Securities Exchange Act of 1934.

The Nature journals press site is at http://press.nature.com

• PDFs for the Articles, Letters, Progress articles, Review articles, Insights and Brief Communications in this issue will be available on the Nature journals press site from 1400 London time / 0900 US Eastern time on the Friday before publication.

• PDFs of News & Views, News Features, Correspondence and Commentaries will be available from 1400 London time / 0900 US Eastern time on the Monday before publication

PICTURES: While we are happy for images from Nature to be reproduced for the purposes of contemporaneous news reporting, you must also seek permission from the copyright holder (if named) or author of the research paper in question (if not).

HYPE: We take great care not to hype the papers mentioned on our press releases, but are sometimes accused of doing so. If you ever consider that a story has been hyped, please do not hesitate to contact us at press@nature.com, citing the specific example.

PLEASE CITE NATURE AND OUR WEBSITE www.nature.com/nature AS THE SOURCE OF THE FOLLOWING ITEMS. IF PUBLISHING ONLINE, PLEASE CARRY A HYPERLINK TO http://www.nature.com/nature

[2] Immunology: Avian flu’s Achilles’ heel (AOP)
DOI: 10.1038/nature05114

***This paper will be published electronically on Nature's website on 16 August at 1800 London time / 1300 US Eastern time (which is also when the embargo lifts) as part of our AOP (ahead of print) programme. Although we have included it on this release to avoid multiple mailings it will not appear in print on 17 August, but at a later date.***

The molecular structure of a key avian influenza protein reveals a quirk that could be used to design more potent drugs against pandemic flu, report John Skehel and his colleagues in a paper to be published online this week by Nature.

The H5N1 virus that is spreading around the globe gets its initials from the haemagglutinin (H) and neuraminidase (N) proteins on the coat of the virus, and each protein comes in several different forms. The neuraminidase helps the virus to escape infected cells and attack new ones, and is targeted by the drugs oseltamivir (Tamiflu) and zanamivir (Relenza). But these drugs were designed on the basis of the crystal structures for neuraminidases N2 and N9 — the only structures available until now.

The structure of the N1 enzyme — and closely related N4 and N8 enzymes — exposes a key difference in enzyme configuration when compared with the previous structures: a cavity in one corner of the active site that closes when it locks onto its target proteins. This difference could potentially be exploited to design much-needed drugs that bind more snugly into this active site, and perhaps sidestep the drug resistance that some viruses have already acquired to Tamiflu.
CONTACT

John Skehel (National Institute of Medical Research, London, UK)
Tel: +44 20 8816 2525; E-mail: skeheljj@nimr.mrc.ac.uk

[3] Avian flu: Stopping the silent spread (p757)

The use of unvaccinated 'sentinel' birds may not always prevent the silent spread of the H5N1 virus through vaccinated flocks, according to a Brief Communication in Nature this week. There are growing concerns that, despite effective protection in individual birds, vaccination may not be sufficient to stop outbreaks across an entire flock, with transmission of the virus going undetected.

Nicholas J. Savill and colleagues used mathematical modelling of data to track the spread of H5N1 through flocks. They report that 90% of birds need to be protected to reduce the probability of an outbreak by 50%, but that this could increase the risk of outbreaks escaping detection. They show that although outbreaks become less likely within the flock itself, there is a higher chance of between-flock transmission.

The practice of placing and monitoring unvaccinated sentinel birds in flocks can mitigate, but not completely eliminate, these negative effects. A highly effective vaccine and vaccine delivery system must be combined with rapid detection and removal of infected flocks, the team concludes.
CONTACT

Nicholas Savill (University of Edinburgh, Edinburgh, UK)
Tel: +44 131 6507573; E-mail: nick.savill@ed.ac.uk


PRESS CONTACTS…

For North America and Canada
Katie McGoldrick, Nature Washington
Tel: +1 202 737 2355; E-mail: k.mcgoldrick@naturedc.com

For Japan, Korea, China, Singapore and Taiwan
Rinoko Asami, Nature Tokyo
Tel: +81 3 3267 8751; E-mail: r.asami@naturejpn.com

For the UK/Europe/other countries not listed above
Katherine Anderson, Nature London
Tel: +44 20 7843 4502; E-mail k.anderson@nature.com

About Nature Publishing Group

Nature Publishing Group (NPG) is a division of Macmillan Publishers Ltd, dedicated to serving the academic, professional scientific and medical communities. NPG's flagship title, Nature, is the world's most highly-cited weekly multidisciplinary journal and was first published in 1869. Other publications and services include Nature research journals, Nature Reviews, Nature Clinical Practice, a range of prestigious academic journals, including society-owned publications, news content from news@nature.com and scientific career information from Naturejobs.

NPG is a global company, with headquarters in London and offices in New York, San Francisco, Washington DC, Boston, Tokyo, Paris, Munich, Hong Kong, Melbourne, Gurgaon, Mexico City and Basingstoke. For more information, please go to www.nature.com.

Associated links

Journal information

NATURE

Keywords associated to this article: avian flu
Create Account...